Biotech News
Related news
ERASErasca2026-11-04 13:30 EST
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
URGNUroGen Pharma2026-11-03 13:00 EST
UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
GERNGeron2026-11-03 13:00 EST
Geron Corporation to Participate in the Stifel 2026 Healthcare Conference
COGTCogent Biosciences2026-10-27 20:01 EST
Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference
PRLDPrelude Therapeutics2026-10-16 20:01 EST
Prelude Therapeutics to Participate in the Chardan Healthcare Conference
ACRVAcrivon Therapeutics2026-11-04 21:30 EST
Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
MMSIMerit Medical2026-11-05 14:25 EST
Merit Medical Presents Real-World Data from the AVF Cohort of the WRAP Global Registry
ERASErasca2026-11-03 13:00 EST
Erasca to Present at Upcoming Conferences in November
STROSutro Biopharma2026-10-12 12:00 EST
Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference
SNDXSyndax Pharmaceuticals2026-11-04 14:01 EST
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
Erasca
RAS/MAPK Precision Oncology Erasca is a clinical-stage precision-oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Its portfolio is designed to address genetically defined tumors through direct RAS inhibition. ERAS-0015 ERAS-0015 is a pan-RAS molecular glue being evaluated in the AURORAS clinical program....
Recent company news
ERASErasca2026-11-04 13:30 EST
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
ERASErasca2026-11-03 13:00 EST
Erasca to Present at Upcoming Conferences in November
ERASErasca2026-09-10 12:00 EST
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
ERASErasca2026-09-08 11:00 EST
Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
ERASErasca2026-08-24 12:00 EST
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
Stock data
- Close
- 13.27 USD
- Market cap
- 4.19B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States